January 11, 2023: The FDA has authorized Airsupra, an inhalation aerosol containing albuterol and budesonide, for the treatment or prevention of bronchoconstriction as needed, as well as to lower the risk of asthma attacks in individuals with asthma who are 18 years of age or older. The medication known as Airsupra is a combination of the beta-2 adrenergic agonist albuterol and the corticosteroid budesonide. It is the first short-acting beta-agonist and inhaled corticosteroid (ICS) combo to be approved in the United States. Furthermore, Airsupra is the first ICS-containing medicine approved in the United States for use as an asthma relief (as opposed to a controller).
September 27, 2023: Global healthcare leader Viatris Inc. and clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma, Inc., which develops and markets small-molecule therapies for the treatment of retinal and refractive eye disorders, announced that the FDA in the United States has approved RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis caused by parasympatholytic (like tropicamide) or adrenergic agonists (like phenylephrine).
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 2541
Published Date: Nov 24, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the growth of the market are surge in prevalence of cardiovascular disease, rising geriatric population, and growing research & development for the launch of new products.
The market size of adrenergic drug is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2024-2036.
The major players in the market are Pfizer, Inc., Novartis AG, GSK plc., AstraZeneca, and others.
The bronchodilators segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.